Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Algert Global LLC

Algert Global LLC boosted its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 59.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 180,122 shares of the company's stock after acquiring an additional 67,275 shares during the quarter. Algert Global LLC owned about 0.20% of Arcus Biosciences worth $2,682,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Barclays PLC lifted its stake in Arcus Biosciences by 49.0% during the 3rd quarter. Barclays PLC now owns 118,693 shares of the company's stock worth $1,816,000 after acquiring an additional 39,015 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Arcus Biosciences by 2.6% during the third quarter. JPMorgan Chase & Co. now owns 43,685 shares of the company's stock worth $668,000 after purchasing an additional 1,117 shares in the last quarter. Nordea Investment Management AB boosted its stake in shares of Arcus Biosciences by 2.5% in the fourth quarter. Nordea Investment Management AB now owns 218,930 shares of the company's stock valued at $3,245,000 after purchasing an additional 5,246 shares during the period. R Squared Ltd purchased a new position in shares of Arcus Biosciences in the fourth quarter valued at approximately $26,000. Finally, Principal Financial Group Inc. increased its stake in Arcus Biosciences by 3.1% during the 4th quarter. Principal Financial Group Inc. now owns 263,517 shares of the company's stock worth $3,924,000 after buying an additional 7,906 shares during the period. Institutional investors and hedge funds own 92.89% of the company's stock.

Wall Street Analysts Forecast Growth

RCUS has been the topic of several analyst reports. Wedbush reiterated an "outperform" rating and issued a $33.00 price objective on shares of Arcus Biosciences in a research note on Wednesday, May 7th. Morgan Stanley decreased their price objective on Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating for the company in a research note on Friday. Bank of America cut their target price on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 19th. HC Wainwright upgraded shares of Arcus Biosciences from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $18.00 to $24.00 in a research note on Wednesday, February 26th. Finally, Wells Fargo & Company lowered their price target on shares of Arcus Biosciences from $29.00 to $26.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $25.67.

Arcus Biosciences Price Performance

Shares of Arcus Biosciences stock traded down $0.28 during trading on Tuesday, reaching $8.52. The company's stock had a trading volume of 187,506 shares, compared to its average volume of 833,437. The business has a 50 day moving average price of $8.38 and a 200-day moving average price of $12.30. Arcus Biosciences, Inc. has a 12-month low of $6.50 and a 12-month high of $18.98. The company has a market capitalization of $902.14 million, a P/E ratio of -2.70 and a beta of 0.88. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.14) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.12). Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company had revenue of $28.00 million for the quarter, compared to analyst estimates of $38.61 million. During the same period last year, the company earned ($0.05) earnings per share. The business's revenue for the quarter was down 80.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, Director Yasunori Kaneko purchased 20,000 shares of Arcus Biosciences stock in a transaction on Thursday, February 27th. The shares were bought at an average price of $10.06 per share, with a total value of $201,200.00. Following the completion of the acquisition, the director now directly owns 28,400 shares of the company's stock, valued at approximately $285,704. This trade represents a 238.10% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Terry J. Rosen purchased 19,800 shares of the stock in a transaction dated Thursday, February 27th. The stock was acquired at an average price of $10.18 per share, for a total transaction of $201,564.00. Following the completion of the transaction, the chief executive officer now directly owns 2,554,160 shares of the company's stock, valued at approximately $26,001,348.80. The trade was a 0.78% increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by corporate insiders.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.